Coverage determinants of breast cancer screening in Flanders: an evaluation of the past decade.


Journal

International journal for equity in health
ISSN: 1475-9276
Titre abrégé: Int J Equity Health
Pays: England
ID NLM: 101147692

Informations de publication

Date de publication:
27 11 2020
Historique:
received: 13 04 2020
accepted: 11 11 2020
entrez: 28 11 2020
pubmed: 29 11 2020
medline: 30 4 2021
Statut: epublish

Résumé

Breast cancer (BC) is the most common cancer in women in the developed world. In order to find developing cancers in an early stage, BC screening is commonly used. In Flanders, screening is performed in and outside an organized breast cancer screening program (BCSP). However, the determinants of BC screening coverage for both screening strategies are yet unknown. To assess the determinants of BC screening coverage in Flanders. Reimbursement data were used to attribute a screening status to each woman in the target population for the years 2008-2016. Yearly coverage data were categorized as screening inside or outside BCSP or no screening. Data were clustered by municipality level. A generalized linear equation model was used to assess the determinants of screening type. Over all years and municipalities, the median screening coverage rate inside and outside BCSP was 48.40% (IQR: 41.50-54.40%) and 14.10% (IQR: 9.80-19.80%) respectively. A higher coverage rate outside BSCP was statistically significantly (P < 0.001) associated with more crowded households (OR: 3.797, 95% CI: 3.199-4.508), younger age, higher population densities (OR: 2.528, 95% CI: 2.455-2.606), a lower proportion of unemployed job seekers (OR: 0.641, 95% CI: 0.624-0.658) and lower use of dental care (OR: 0.969, 95% CI: 0.967-0.972). Coverage rate of BC screening is not optimal in Flanders. Women with low SES that are characterized by younger age, living in a high population density area, living in crowded households, or having low dental care are less likely to be screened for BC in Flanders. If screened, they are more likely to be screened outside the BCSP.

Sections du résumé

BACKGROUND
Breast cancer (BC) is the most common cancer in women in the developed world. In order to find developing cancers in an early stage, BC screening is commonly used. In Flanders, screening is performed in and outside an organized breast cancer screening program (BCSP). However, the determinants of BC screening coverage for both screening strategies are yet unknown.
OBJECTIVE
To assess the determinants of BC screening coverage in Flanders.
METHODS
Reimbursement data were used to attribute a screening status to each woman in the target population for the years 2008-2016. Yearly coverage data were categorized as screening inside or outside BCSP or no screening. Data were clustered by municipality level. A generalized linear equation model was used to assess the determinants of screening type.
RESULTS
Over all years and municipalities, the median screening coverage rate inside and outside BCSP was 48.40% (IQR: 41.50-54.40%) and 14.10% (IQR: 9.80-19.80%) respectively. A higher coverage rate outside BSCP was statistically significantly (P < 0.001) associated with more crowded households (OR: 3.797, 95% CI: 3.199-4.508), younger age, higher population densities (OR: 2.528, 95% CI: 2.455-2.606), a lower proportion of unemployed job seekers (OR: 0.641, 95% CI: 0.624-0.658) and lower use of dental care (OR: 0.969, 95% CI: 0.967-0.972).
CONCLUSION
Coverage rate of BC screening is not optimal in Flanders. Women with low SES that are characterized by younger age, living in a high population density area, living in crowded households, or having low dental care are less likely to be screened for BC in Flanders. If screened, they are more likely to be screened outside the BCSP.

Identifiants

pubmed: 33246477
doi: 10.1186/s12939-020-01323-z
pii: 10.1186/s12939-020-01323-z
pmc: PMC7694412
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

212

Références

Eur J Cancer Prev. 1994 Jan;3 Suppl 1:7-12
pubmed: 8130728
Cancer Epidemiol. 2010 Jun;34(3):309-15
pubmed: 20403737
BMC Cancer. 2019 Oct 28;19(1):1012
pubmed: 31660890
Fam Pract. 2013 Aug;30(4):445-51
pubmed: 23478254
BMC Health Serv Res. 2018 Dec 4;18(1):943
pubmed: 30514273
Am J Public Health. 2014 Jul;104(7):e85-91
pubmed: 24832423
BMC Cancer. 2012 Nov 14;12:518
pubmed: 23151053
Health Psychol Rev. 2015;9(1):42-62
pubmed: 25793490
J Womens Health (Larchmt). 2019 Oct;28(10):1378-1383
pubmed: 30565970
J Am Coll Radiol. 2019 Apr;16(4 Pt B):570-579
pubmed: 30947889
BMJ Open. 2017 Jul 20;7(7):e015042
pubmed: 28729310
J Womens Health (Larchmt). 2019 Aug;28(8):1051-1059
pubmed: 30481098
Prev Med. 2014 Dec;69:280-6
pubmed: 25456812
J Epidemiol Community Health. 2004 Jun;58(6):476-80
pubmed: 15143115
Ann Oncol. 2008 Apr;19(4):614-22
pubmed: 18024988
Patient Educ Couns. 2014 Dec;97(3):410-7
pubmed: 25282326
J Expo Sci Environ Epidemiol. 2007 Jan;17(1):106-21
pubmed: 17033679
Scand J Public Health. 2007;35(5):548-54
pubmed: 17852976
J BUON. 2018 May-Jun;23(3):706-712
pubmed: 30003740
JAMA. 2015 Oct 20;314(15):1615-34
pubmed: 26501537
J Med Screen. 2012;19 Suppl 1:72-82
pubmed: 22972813
Int J Cancer. 2004 Feb 20;108(5):754-60
pubmed: 14696103
BMJ Open. 2015 Jul 24;5(7):e007735
pubmed: 26209119
BMC Health Serv Res. 2016 Sep 23;16(1):519
pubmed: 27663642
N Engl J Med. 2015 Jun 11;372(24):2353-8
pubmed: 26039523
Cancer. 2013 Nov 1;119(21):3847-53
pubmed: 23943323
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Rev Epidemiol Sante Publique. 2012 Dec;60(6):421-30
pubmed: 23146369
Int J Cancer. 2005 Jan 20;113(3):464-70
pubmed: 15455383
BMC Oral Health. 2018 Aug 23;18(1):147
pubmed: 30139349
Int J Cancer. 2008 Jan 15;122(2):418-23
pubmed: 17893881
Cancer Epidemiol. 2019 Jun;60:77-85
pubmed: 30927689
J Community Health. 2012 Jun;37(3):626-31
pubmed: 22119996
PLoS One. 2018 Mar 27;13(3):e0194409
pubmed: 29584742

Auteurs

L Ding (L)

Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Department of Social Epidemiology and Health Policy, University of Antwerp, Antwerp, Belgium.

S Jidkova (S)

Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.
Center for Cancer Detection, Flanders, Belgium.

M J W Greuter (MJW)

Department of Radiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Department of Robotics and Mechatronics, University of Twente, Enschede, The Netherlands.

K Van Herck (K)

Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.
Center for Cancer Detection, Flanders, Belgium.

M Goossens (M)

Center for Cancer Detection, Flanders, Belgium.

P Martens (P)

Center for Cancer Detection, Flanders, Belgium.

G H de Bock (GH)

Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. g.h.de.bock@umcg.nl.

G Van Hal (G)

Department of Social Epidemiology and Health Policy, University of Antwerp, Antwerp, Belgium.
Center for Cancer Detection, Flanders, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH